© 2020 MJH Life Sciences, Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
MPNs
Ropeginterferon Provides Improved Hematocrit Control Over Phlebotomy Alone in Low-Risk PV
June 14, 2020
"This interim analysis demonstrated ropeginterferon in low-risk patients is more efficacious in keeping the hematocrit [at target levels]. In addition, we get a better quality of life and the target was reached with a reduction of phlebotomy needs."
BLA for Ropeginterferon Alfa-2b as PV Treatment Accepted by the FDA
June 04, 2020
"We believe ropeginterferon alfa-2b could become an important new therapeutic tool and look forward to engaging with the regulators in our efforts to introduce this option to the underserved PV community in the United States."
Ruxolitinib Plus Post-Transplant Cyclophosphamide Controls GVHD in Myelofibrosis
May 20, 2020
“In this study, we evaluated ruxolitinib as a bridge, relapse, and GVHD prevention agent in patients with myelofibrosis. The regimen was well tolerated, with an acceptable rate of organ toxicity."
Blast Phase Not Stalled With Ruxolitinib Treatment in Myelofibrosis, Study Shows
May 20, 2020
A new analysis of nearly 600 patients with myelofibrosis found patients who take ruxolitinib progress to blast phase at approximately the same rates as those who are ruxolitinib-naïve.
Momelotinib May Fill Treatment Gap for Anemia in Myelofibrosis
May 19, 2020
Momelotinib for the treatment of patients with myelofibrosis may address concerns with the development of cytopenias, an issue no approved therapy has been able to solve.
Steroid-Refractory Chronic GVHD Requires More Treatment Options
May 14, 2020
Corey S. Cutler, MD, MPH, discusses the current treatment options for patients with chronic graft-versus-host-disease and highlighted some upcoming research.
The Value of Prognostication in the Modern Management of Myelofibrosis
May 13, 2020
In an interview with Targeted Oncology, Verstovsek, medical oncologist and professor, Department of Leukemia, University of Texas MD Anderson Cancer Center, discussed mutational profiling for myelofibrosis and how the information obtained can be valuable for clinical management of the disease.
Investigators Study JAK Inhibitors in Patients With Myelofibrosis
May 11, 2020
Ruben Mesa, MD, discusses the role of JAK inhibitors, which are currently being investigated in patients with myelofibrosis. He also spoke to what the future of this treatment landscape may be.
Young Adult and Pediatric Patients With MPNs Should Remain Hopeful, Expert Says
April 13, 2020
In an interview with Targeted Oncology, Nicole Kucine, MD, MS, discussed the findings from her review of the literature on children, adolescents, and young adults with myeloproliferative neoplasms. She highlighted what next steps are needed in this space in terms of research and what a community oncologist should do should for younger patients with myeloproliferative neoplasms.
Anti-Cancer Agents as Frontline Treatment of MPNs Lead to Higher Probability of Non-Melanoma Skin Cancers
April 10, 2020
Exposure to ruxolitinib, hydroxyurea, and pipobroman as first-line treatment of Philadelphia-negative myeloproliferative neoplasms alone or in combination with other cytoreductive treatment may increase the probability of patients developing non-melanoma skin cancer, highlighting a need for active dermatological surveillance of these patients, according to findings from the MPN-K study, published in Leukemia.